Plain Language Summary

Citation: Burchard J, et al. Disease-modifying effects of centrally administered adrabetadex for treatment of Niemann-Pick disease type C. Poster presented at: National Niemann-Pick Disease Foundation (NNPDF) Family and Medical Conference; July 2026.

Plain Language Summary: Results of laboratory and animal studies showing that adrabetadex (formerly VTS-270, cyclodextrin) does not just clear trapped cholesterol, it also repairs downstream damage to brain cells, improves the protective insulation around nerve fibers, preserves critical neurons, slows neurological decline, and extends survival in infantile-onset Niemann-Pick Disease Type C (I-NPC) animal models.

What is this study about?

Earlier research showed that adrabetadex clears the cholesterol trapped inside brain cells. This study asked the next question: once cholesterol starts moving normally again, what happens in the brain? Does clearing the cholesterol translate into real, measurable improvements in how brain cells look, function, and survive?

In NPC, impaired cholesterol trafficking does not just affect one cell type, it disrupts the entire brain environment. Neurons (the cells that transmit signals), oligodendrocytes (the cells that produce the protective myelin sheath around nerve fibers), and other supporting cells all depend on proper cholesterol handling. When cholesterol gets stuck within part of a cell, it cascades into multiple problems: nerve fibers lose their protective insulation (demyelination), specific neurons critical for coordination die off, inflammation increases, and the brain's signaling networks deteriorate. This study looked at whether adrabetadex, an investigational treatment not yet approved by the U.S. Food and Drug Administration (FDA), can reverse or slow these downstream consequences.

What did the study do?

The researchers used three complementary experimental approaches using established I-NPC mouse models: a cell culture study, a detailed brain tissue analysis, and a whole-animal function and survival study.

What the study found:

Across all three approaches, adrabetadex demonstrates disease-modifying effects, meaning it not only improves measurable signals in the laboratory, but produces real improvements in brain cell health, neurological function and survival:

• Survival is extended: Adrabetadex significantly extends survival even when treatment began after symptoms had already appeared. Untreated I-NPC mice survived a median of around 82 days, and mice treated with adrabetadex survived a median of around 120 days, representing a roughly 50% increase in lifespan. 
• Disease progression slows: Treated I-NPC mice show significantly slower neurological decline on a standardized scale tracking tremor, coordination, and movement, compared to untreated I-NPC mice, with greater benefit at higher doses. 
• Brain health improves Adrabetadex protects brain cells of I-NPC mice in several ways, including:
  1. Increasing myelin basic protein, a key component of the protective insulation around nerve fibers,
  2. Preserving Purkinje neurons in the cerebellum, cells essential for coordinated movement 
  3. Reducing FABP3, a protein released into spinal fluid when brain cells break down, indicating less ongoing neurodegeneration 

In laboratory cell cultures that mimic NPC conditions, adrabetadex improved cholesterol movement, nerve insulation, connections between neurons, and cell survival, with a greater benefit shown at higher concentrations. 

Why does this matter?

Together, these findings demonstrate that adrabetadex is not simply changing measurable signals in the laboratory, it is producing real improvements in brain biology and function. The fact that these effects were observed even when treatment began after symptoms had already appeared is particularly meaningful, because in clinical practice, many children with I-NPC are not diagnosed until after neurological symptoms have developed.

The results also begin to explain the link between what the treatment does at the cellular level and the meaningful outcomes of slowed progression and improved survival. By re-establishing cholesterol trafficking, adrabetadex leads to improved myelination, healthier neurons, less ongoing neurodegeneration, and ultimately, longer survival.

What this means for patients:

This research provides strong scientific evidence that adrabetadex does more than simply move cholesterol, it preserves the brain structures that NPC damages. The data support the idea that adrabetadex acts as a true disease-modifying therapy: one that addresses the biological cause of NPC and slows the downstream chain of damage that causes children to lose function and, ultimately, their lives.

Taken together with the companion poster on the mechanism of action, these two studies paint a complete picture: adrabetadex reaches the whole brain, clears trapped cholesterol, and as a direct consequence of that clearance, preserves myelin, protects neurons, reduces neurodegeneration, slows clinical decline, and extends survival in animal models.

A disease-modifying therapy is one that slows or changes the course of a disease, rather than simply treating symptoms. These findings support the ongoing clinical evaluation of adrabetadex and its potential role as a foundational therapy in I-NPC, one that targets the disease's cause and creates a biological foundation upon which other complementary treatments can be layered.

What this means for families:

These studies suggest that adrabetadex does more than temporarily improve symptoms. By restoring the normal movement of cholesterol inside brain cells, it may help protect the brain from the ongoing damage caused by NPC.

In animal models, this led to healthier brain cells, better preservation of the protective coating around nerves, slower neurological decline, and longer survival. Together, these findings help explain why children treated with adrabetadex in clinical studies have shown slower disease progression and improved survival.

For families, this provides greater confidence that adrabetadex is addressing the underlying cause of NPC rather than simply managing its consequences. While these laboratory findings need to be interpreted alongside clinical studies in patients, they strengthen the scientific foundation for adrabetadex as a disease-modifying therapy and support its continued evaluation as a foundational treatment for I-NPC.